An fMRI Study of Ketamine in Treatment-Resistant Depression

ID Number 08-0874

Principal Investigator(s)
James Murrough

Department(s) or Division(s)

Research Entity
Mood and Anxiety Disorders Program - MAP


The purpose of this study is to investigate the antidepressant mechanism of action of ketamine in patients with treatment-resistant major depression (TRD) using functional magnetic resonance imaging (fMRI). Ketamine is a N-methyl-D-aspartate (NMDA) glutamate receptor antagonist that has demonstrated rapid-acting antidepressant properties after a single intravenous (IV) infusion in patients with treatment-resistant major depression (TRD).The neurobiological mechanisms of the antidepressant effects of ketamine are unknown and represent a critical area of research in the pathophysiology and treatment of major depression.

Contact Information
Jaclyn Schwartz
(212) 241-3116

Recruiting Patients: Yes